{
    "clinical_study": {
        "@rank": "131023", 
        "arm_group": [
            {
                "arm_group_label": "RXI-109", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to evaluate the safety and tolerability of multiple (3)\n      intradermal doses of RXI-109 at small surgical incisions in the abdominal skin of healthy\n      volunteers.  The effect of RXI-109 versus placebo on scarring at these incision sites will\n      be evaluated visually, histologically, and by biomarker analysis."
        }, 
        "brief_title": "Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cicatrix", 
            "Scar Prevention"
        ], 
        "condition_browse": {
            "mesh_term": "Cicatrix"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females, 21-50 years of age\n\n          -  General good health; if female not pregnant or lactating\n\n          -  Phototype 3 and above based on the Fitzpatrick scale.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating\n\n          -  Use of tobacco or nicotine-containing products within 1 month prior to enrollment and\n             while on study\n\n          -  Type 1 or 2 diabetes mellitus\n\n          -  A history or presence of any medical condition or therapy that would make the subject\n             an unsafe candidate in the opinion of the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780077", 
            "org_study_id": "RXI-109-1202"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "RXI-109", 
                    "Placebo"
                ], 
                "description": "Multiple intradermal injections of RXI-109 at incision sites", 
                "intervention_name": "RXI-109", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "RXI-109", 
                    "Placebo"
                ], 
                "description": "Multiple intradermal injections of placebo at incision sites", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Scar", 
            "Scar prevention", 
            "Fibrosis"
        ], 
        "lastchanged_date": "January 6, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Single Center, Randomized, Double-Blind, Ascending, Multi-Dose, Within-Subject Controlled Study of RXI-109 for the Treatment of Incision Scars Made in the Abdominal Skin of Healthy Subjects", 
        "other_outcome": {
            "description": "Analysis of immunohistochemical analysis of biomarkers common to the scar formation pathway.", 
            "measure": "To assess the timeline and levels of biomarkers", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate safety and tolerability of multiple administrations of RXI-109 at the site of intradermal injection.  Examine and assess any and all local and systemic toxicities", 
            "measure": "To assess the safety and tolerability of multiple intradermal administrations of RXI-109", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "removed_countries": {
            "country": "Honduras"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780077"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Assess visual outcome and histology of scars.  Digital images of the RXI-109 and placebo-treated incisions/scars will be captured and scored.", 
            "measure": "To assess the effect of multiple intradermal administrations of RXI-109 on scar formation", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "source": "RXi Pharmaceuticals, Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RXi Pharmaceuticals, Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}